Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
School of Medicine, National Yang Ming University, Taipei, Taiwan.
J Neurooncol. 2020 Feb;146(3):417-426. doi: 10.1007/s11060-019-03360-3. Epub 2020 Feb 4.
The failure of immune checkpoint inhibitor (ICPi) on glioblastoma (GBM) treatment underscores the need for improving therapeutic strategy. We aimed to change tumor associated macrophage (TAM) from M2 type (anti-inflammatory) to M1 (pro-inflammatory) type to increase the therapeutic response of ICPi. We proposed that combined rapamycin (R) and hydroxychloroquine (Q) preferentially induce M2 cells death, as fatty acid oxidation was their major source of energy.
Macrophage polarization was characterized on mice and human macrophage cell lines by specific cytokines stimulation with or without RQ treatment under single culture or co-culture with GBM cell lines. Tumor sizes were evaluated on subcutaneous and intracranial GL261 mice models with or without RQ, anti-PD1 mAb treatment. Tumor volumes assessed by MRI scan and proportions of tumor infiltrating immune cells analyzed by flow cytometry were compared.
In vitro RQ treatment decreased the macrophages polarization of M2, increased the phagocytic ability, and increased the lipid droplets accumulation. RQ treatment decreased the expression levels of CD47 and SIRPα on tumor cells and macrophage cells in co-culture experiments. The combination of RQ and anti-PD1 treatment was synergistic in action. Enhanced the intra-tumoral M1/M2 ratio, the CD8/CD4 ratio in the intracranial GL261 tumor model after RQ treatment were evident.
We provide a rationale for manipulating the macrophage phenotype and increased the therapeutic effect of ICPi. To re-educate and re-empower the TAM/microglia opens an interesting avenue for GBM treatment.
免疫检查点抑制剂(ICPi)在治疗胶质母细胞瘤(GBM)方面的失败突显了需要改进治疗策略。我们旨在将肿瘤相关巨噬细胞(TAM)从 M2 型(抗炎)转变为 M1 型(促炎),以增加 ICPi 的治疗反应。我们提出,联合雷帕霉素(R)和羟氯喹(Q)优先诱导 M2 细胞死亡,因为脂肪酸氧化是它们的主要能量来源。
通过特异性细胞因子刺激,在单独培养或与 GBM 细胞系共培养的情况下,用或不用 RQ 处理,在小鼠和人巨噬细胞系中对巨噬细胞极化进行特征描述。用或不用 RQ、抗 PD1 mAb 处理,在皮下和颅内 GL261 小鼠模型中评估肿瘤大小。通过 MRI 扫描评估肿瘤体积,并通过流式细胞术分析肿瘤浸润免疫细胞的比例。
体外 RQ 处理降低了 M2 型巨噬细胞的极化,增加了吞噬能力,并增加了脂滴的积累。RQ 处理降低了共培养实验中肿瘤细胞和巨噬细胞上 CD47 和 SIRPα 的表达水平。RQ 和抗 PD1 联合治疗具有协同作用。增强了颅内 GL261 肿瘤模型中肿瘤内的 M1/M2 比值和 CD8/CD4 比值。
我们为操纵巨噬细胞表型和提高 ICPi 的治疗效果提供了依据。重新教育和增强 TAM/小胶质细胞为 GBM 治疗开辟了一条有趣的途径。